Fig. 2From: Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE studyCost-effectiveness acceptability curve of PGx-guided group vs control. Y-axis represents the probability of PGx technology to be cost-effective; X-axis represents the willingness-to-pay for a QALYBack to article page